Magic mushrooms, long considered sacred by the Indigenous Mazatec in Mexico, become the subject of scientific studies measuring the intense effects of its Psilocybin and its potential therapeutic use. In the second episode, we are introduced to Ben, who’s battled with crippling Obsessive-Compulsive Disorder (OCD) his entire life. When he had his firstborn, Ben’s life became full of panic attacks regarding his son’s safety, and he knew something had to change. Ben signed up for a psilocybin-assisted therapy clinical trial which was testing whether the psychedelic could help people with severe OCD. In the session under the influence of psilocybin, Ben felt decomposed and eventually grew into a tree. While living as a tree, he saw his human self, playing with his child. Though this sounds scary, from Ben’s perspective, it was beautiful. He was one with the universe, seeing himself in the ultimate third-person perspective. Finally, he saw how it could be different if he didn’t let his OCD control him. And several months out, all the symptoms disappeared. Ben’s story is one of many told in this series, which gives hope that help is right around the corner for the millions who suffer —often in silence— with debilitating mental disorders. But Michael Pollan’s work is showcasing the success stories. Often, even in the most successful trials, psychedelic-assisted therapy only helps up to a third of people enter remission. More frequently, patients are helped —sometimes substantially— but they still suffer with their illnesses and some people aren’t helped at all.
Where will loved ones spend their last days? Who will be in the room? What feelings and secrets need to be shared with family before it is too late? Acclaimed filmmakers Rob Epstein and Jeffrey Friedman probe these questions and more in the context of two San Francisco Bay Area medical facilities on the forefront of creating new paradigms for end of life decisions with grace. Filmed and edited in intimate vérité style, 'End Game' follows visionary medical practitioners who are working on the cutting edge of life and death and are dedicated to changing our thinking about both.
With more board configurations than there are atoms in the observable universe, the ancient Chinese game of 'Go' has long been considered a grand challenge for artificial intelligence. On March 9, 2016, the worlds of Go and AI collided in South Korea for an extraordinary best-of-five-game competition, coined the Google DeepMind Challenge Match. Hundreds of millions of people around the world watched as a legendary Go master took on an unproven AI challenger for the first time in history. AlphaGo chronicles a journey from the halls of Cambridge, through the backstreets of Bordeaux, past the coding terminals of DeepMind in London, and, ultimately, to the seven-day tournament in Seoul. As the drama unfolds, more questions emerge: What can artificial intelligence reveal about a 3000-year-old game? What can it teach us about human mind?
In the second episode, we are introduced to Ben, who’s battled with crippling Obsessive-Compulsive Disorder (OCD) his entire life. When he had his firstborn, Ben’s life became full of panic attacks regarding his son’s safety, and he knew something had to change. Ben signed up for a psilocybin-assisted therapy clinical trial which was testing whether the psychedelic could help people with severe OCD. In the session under the influence of psilocybin, Ben felt decomposed and eventually grew into a tree. While living as a tree, he saw his human self, playing with his child. Though this sounds scary, from Ben’s perspective, it was beautiful. He was one with the universe, seeing himself in the ultimate third-person perspective. Finally, he saw how it could be different if he didn’t let his OCD control him. And several months out, all the symptoms disappeared.
Ben’s story is one of many told in this series, which gives hope that help is right around the corner for the millions who suffer —often in silence— with debilitating mental disorders. But Michael Pollan’s work is showcasing the success stories. Often, even in the most successful trials, psychedelic-assisted therapy only helps up to a third of people enter remission. More frequently, patients are helped —sometimes substantially— but they still suffer with their illnesses and some people aren’t helped at all.